Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-31

Study Completion Date

2019-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phase IV, Single-Arm, Open-Label Study Evaluating Bone Mineral Density in HIV-1-Infected Adults ≥50 Years Old Switching from EVG/COBI/FTC/TAF (Genvoya) or EVG/COBI/FTC/TDF (Stribild) to ABC/DTG/3TC (Triumeq)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen

NCT02478632

HIV Infections

COMPLETED PHASE3

A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects

NCT01850212

HIV Infections

COMPLETED

Bone Health in Aging HIV Infected Women

NCT02815566

Osteoporosis HIV Menopause

COMPLETED PHASE4

Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In Hiv-1-Infected Subjects With Loss Of Bone Mineral Density

NCT01153217

HIV

COMPLETED PHASE3

Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV Patients Treated With Tenofovir +/- Emtricitabine

NCT01813292

HIV Seropositivity

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Phase IV, Single-Arm, Open-Label Study Evaluating Bone Mineral Density in HIV-1-Infected Adults ≥50 Years Old Switching from EVG/COBI/FTC/TAF (Genvoya) or EVG/COBI/FTC/TDF (Stribild) to ABC/DTG/3TC (Triumeq)

To evaluate the impact on BMD, as measured by DEXA over 48 weeks, of switching from an INSTI-based regimen with either TDF or TAF to a regimen of ABC/DTG/3TC (administered as commercial Triumeq) in chronic HIV-infected patients over the age of 50

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infection, Human Immunodeficiency Virus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Triumeq

Single Arm, Open Label

Group Type OTHER

Triumeq

Intervention Type DRUG

Open Label, Switch to Triumeq (ABC/DTG/3TC)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Triumeq

Open Label, Switch to Triumeq (ABC/DTG/3TC)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Documented HIV-1 infection;
2. At least 50 years of age;
3. Currently on a stable antiretroviral regimen (for ≥3 months preceding Screening) of either EVG/COBI/FTC/TAF (Genvoya) or EVG/COBI/FTC/TDF (Stribild);
4. HIV is currently suppressed, defined as:

1. Plasma HIV-1 RNA \<50 c/mL for ≥3 months preceding Screening; AND
2. Plasma HIV-1 RNA \<50 copies/mL at the Screening assessment; INCL 5. Documentation that the participant is negative for the human leukocyte antigen (HLA)-B\*5701 allele.

Exclusion Criteria

1. Pregnant, breastfeeding, or planning to become pregnant during the study period;
2. Bilateral hip replacement;
3. Exceeds weight limit for DEXA equipment (i.e., weighs \>350 lbs or \>159 kg);
4. History or presence of allergy to the study treatment (Triumeq) or any of its components (to ABC, DTG, or 3TC);
5. Active Centers for Disease Control and Prevention (CDC) Category C HIV-1 disease (see Section 17.1 for definition), with the exception of cutaneous Kaposi's sarcoma, not requiring systemic therapy and historic CD4+ cell counts of \<200 cells/mm3;
6. Positive for hepatitis B virus surface antigen (HBsAg) at Screening;
7. Ongoing malignancies (other than localized malignancies, such as cutaneous Kaposi's sarcoma, basal cell carcinoma, cervical intraepithelial neoplasia);
8. Significant suicidal risk in the investigator's opinion;
9. Metabolic disease;
10. Treatment with HIV immunotherapeutic vaccine within 90 days of Screening;
11. Radiation, cytotoxic chemotherapy, or any immunomodulator (that alters immune responses) within 28 days of Screening;
12. Exposure to any experimental drug or vaccine within 28 days or 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to first dose of study treatment on Day 1;
13. History of use of only mono or dual NRTI therapy prior to starting combination ART for the treatment of HIV infection (except that prior NRTI use for the purpose of pre-exposure prophylaxis \[PrEP\] or postexposure prophylaxis \[PEP\] is not excluded);
14. Became HIV-positive (i.e., had a detectable plasma HIV-1 viral load) while taking PrEP or PEP;
15. Documented resistance to any component of the study treatment (ABC, DTG, or 3TC) as indicated by either:

1. Historical genotype in the participant's medical record; OR
2. Genotype obtained by GenoSure Archive evaluation at Screening;
16. Any verified screening Grade 4 laboratory abnormality that in the investigator's opinion is clinically significant;
17. Moderate to severe hepatic impairment (Class B or greater) as determined by Child-Pugh classification;
18. Either of the following liver chemistry elevations:

1. Alanine amintotransferase (ALT) ≥5 x the upper limit of normal (ULN); OR
2. ALT ≥3 x ULN and bilirubin ≥1.5 x ULN (with \>35% direct bilirubin);
19. Creatinine clearance (CrCl) of \<50 mL/min (calculated by CockroftGault equation)
20. QT interval corrected for heart rate according to Bazett's formula (QTcB) ≥450 msec or QTcB ≥480 msec for participants with bundle branch block;
21. Any other condition or substance use that in the opinion of the investigator places the participants at undue risk from participation in the study or that may negatively impact the integrity of the study analyses.

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No